T1	Participants 416 561	Patients with completely resected (stage IB, II, or IIIA) NSCLC stratified by stage, histology, sex, postoperative radiotherapy, and chemotherapy
T2	Participants 133 201	patients with completely resected non-small-cell lung cancer (NSCLC)
T3	Participants 758 787	503 of 1,242 planned patients
T4	Participants 1278 1335	344 patients with epidermal growth factor receptor (EGFR)
